Heather Joy Green

Heather Joy Green

Auto-generated profile, based on publicly available information

Heather Joy Green

School of Applied Psychology, Gold Coast Campus, Griffith University

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2002 in BJU International
Verified
Journal Article
Closed access
PDF file
HGH.J. Green
H.J. Green
Kenneth PakenhamKenneth Pakenham
Kenneth Pakenham
BHB.C. Headley
B.C. Headley
JYJ. Yaxley
J. Yaxley
DND.L. Nicol
D.L. Nicol
RGR.A. Gardiner
R.A. Gardiner

10 March 2015 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
MOMiyuki Ono
Miyuki Ono
JOJames M. Ogilvie
James M. Ogilvie
JWJennifer S. Wilson
Jennifer S. Wilson
HGHeather J. Green
Heather J. Green
SCSuzanne K. Chambers
Suzanne K. Chambers
DSDavid Shum
David Shum
A meta-analysis was performed to quantify the magnitude and nature of the association between adjuvant chemotherapy and performance on a range of cognitive domains among breast cancer patients. A total of 27 studies (14 cross-sectional, 8 both cross-sectional and prospective and 5 prospective) were included in the analyses, involving 1562 breast cancer patients who had undergone adjuvant chemotherapy and 2799 controls that included breast cancer patients who did not receive adjuvant chemotherapy. A total of 737 effect sizes (Cohen’s d) were calculated for cross-sectional and prospective longitudinal studies separately and classified into eight cognitive domains. The mean effect sizes varied across cross-sectional and prospective longitudinal studies (ranging from –1.12 to 0.62, and –0.29 to 1.12, respectively). Each cognitive domain produced small effect sizes for cross sectional and prospective longitudinal studies (ranging from –0.25 to 0.41). Results from cross-sectional studies indicated a significant association between adjuvant chemotherapy and cognitive impairment that held across studies with varied methodological approaches. For prospective studies, results generally indicated that cognitive functioning improved over time after receiving adjuvant chemotherapy. Greater cognitive impairment was reported in cross-sectional studies comparing chemotherapy groups with healthy control groups. Results suggested that cognitive impairment is present among breast cancer patients irrespective of a history of chemotherapy. Prospective longitudinal research is warranted to examine the degree and persisting nature of cognitive impairment present both before and after chemotherapy, with comparisons made to participants’ cognitive function prior to diagnosis. Accurate understanding of the effects of chemotherapy is essential to enable informed decisions regarding treatment and to improve quality of life among breast cancer patients.

5 May 2004 in BJU International
Verified
Journal Article
Open access
PDF file
HGH.J. Green
H.J. Green
Kenneth PakenhamKenneth Pakenham
Kenneth Pakenham
BHB.C. Headley
B.C. Headley
JYJ. Yaxley
J. Yaxley
DND.L. Nicol
D.L. Nicol
RGR.A. Gardiner
R.A. Gardiner
OBJECTIVES: To investigate the effects of different management strategies for non‐localized prostate cancer on men's quality of life and cognitive functioning. PATIENTS, SUBJECTS AND METHODS: Men with prostate cancer were randomly assigned to one of four treatment arms: leuprorelin, goserelin, cyproterone acetate (CPA), or close clinical monitoring. In a repeated‐measures design, men were assessed before treatment (baseline) and after 6 and 12 months of treatment. A community comparison group of men of the same age with no prostate cancer participated for the same length of time. The men were recruited from public and private urology departments from university teaching hospitals. All those with prostate cancer who were eligible for hormonal therapy had no symptoms requiring immediate therapy. In all, 82 patients were randomized and 62 completed the 1‐year study, and of the 20 community participants, 15 completed the study. The main outcome measures were obtained from questionnaires on emotional distress, existential satisfaction, physical function and symptoms, social and role function, subjective cognitive function, and sexual function, combined with standard neuropsychological tests of memory, attention, and executive functions. RESULTS: Sexual dysfunction increased for patients on androgen‐suppressing therapies, and emotional distress increased in those assigned to CPA or close clinical monitoring. Compared with before treatment there was evidence of an adverse effect of leuprorelin, goserelin, and CPA on cognitive function. Conclusions: In deciding the timing of androgen suppression therapy for prostate cancer, consideration should be given to potential adverse effects on quality of life and cognitive function.

1 February 2017 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
DVDean Vuksanovic
Dean Vuksanovic
HGHeather J. Green
Heather J. Green
MDMurray Dyck
Murray Dyck
SMShirley A. Morrissey
Shirley A. Morrissey


1 July 2007 in Acta Psychologica
Verified
Journal Article
Closed access
HGHeather J. Green
Heather J. Green
PLPatrick Lemaire
Patrick Lemaire
SDStéphane Dufau
Stéphane Dufau